JP2024521578A5 - - Google Patents
Info
- Publication number
- JP2024521578A5 JP2024521578A5 JP2023575588A JP2023575588A JP2024521578A5 JP 2024521578 A5 JP2024521578 A5 JP 2024521578A5 JP 2023575588 A JP2023575588 A JP 2023575588A JP 2023575588 A JP2023575588 A JP 2023575588A JP 2024521578 A5 JP2024521578 A5 JP 2024521578A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- pharmaceutical composition
- mixture
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208631P | 2021-06-09 | 2021-06-09 | |
| US63/208,631 | 2021-06-09 | ||
| PCT/US2022/032780 WO2022261284A1 (en) | 2021-06-09 | 2022-06-09 | Crystalline abdnaz compositions and methods of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521578A JP2024521578A (ja) | 2024-06-03 |
| JP2024521578A5 true JP2024521578A5 (enExample) | 2025-06-17 |
Family
ID=84425536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575588A Pending JP2024521578A (ja) | 2021-06-09 | 2022-06-09 | 結晶性ａｂｄｎａｚ組成物ならびにその作製方法及び使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240293360A1 (enExample) |
| EP (1) | EP4351567A4 (enExample) |
| JP (1) | JP2024521578A (enExample) |
| KR (1) | KR20240019798A (enExample) |
| CN (1) | CN117835979A (enExample) |
| AU (1) | AU2022289720A1 (enExample) |
| BR (1) | BR112023025535A2 (enExample) |
| CA (1) | CA3221351A1 (enExample) |
| IL (1) | IL309043A (enExample) |
| MX (1) | MX2023014676A (enExample) |
| TW (1) | TW202313001A (enExample) |
| WO (1) | WO2022261284A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3402480T3 (da) | 2016-01-11 | 2021-06-28 | Epicentrx Inc | Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon |
| WO2019164593A2 (en) | 2018-01-08 | 2019-08-29 | Epicentrx, Inc. | Methods and compositions utilizing rrx-001 combination therapy for radioprotection |
| WO2023178283A1 (en) * | 2022-03-18 | 2023-09-21 | Epicentrx, Inc. | Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507842B2 (en) * | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| US8471041B2 (en) | 2010-02-09 | 2013-06-25 | Alliant Techsystems Inc. | Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same |
| DK3402480T3 (da) * | 2016-01-11 | 2021-06-28 | Epicentrx Inc | Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon |
| WO2019164593A2 (en) * | 2018-01-08 | 2019-08-29 | Epicentrx, Inc. | Methods and compositions utilizing rrx-001 combination therapy for radioprotection |
-
2022
- 2022-06-09 US US18/568,625 patent/US20240293360A1/en not_active Abandoned
- 2022-06-09 WO PCT/US2022/032780 patent/WO2022261284A1/en not_active Ceased
- 2022-06-09 AU AU2022289720A patent/AU2022289720A1/en not_active Abandoned
- 2022-06-09 KR KR1020247000307A patent/KR20240019798A/ko active Pending
- 2022-06-09 MX MX2023014676A patent/MX2023014676A/es unknown
- 2022-06-09 IL IL309043A patent/IL309043A/en unknown
- 2022-06-09 JP JP2023575588A patent/JP2024521578A/ja active Pending
- 2022-06-09 CN CN202280054886.0A patent/CN117835979A/zh active Pending
- 2022-06-09 EP EP22821006.8A patent/EP4351567A4/en active Pending
- 2022-06-09 CA CA3221351A patent/CA3221351A1/en active Pending
- 2022-06-09 TW TW111121521A patent/TW202313001A/zh unknown
- 2022-06-09 BR BR112023025535A patent/BR112023025535A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107087409B (zh) | 苯并杂环化合物及其应用 | |
| EP4393490A1 (en) | Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma | |
| JP2023505756A5 (enExample) | ||
| JP2023526451A5 (enExample) | ||
| JP2022544280A5 (enExample) | ||
| JP2024543505A5 (enExample) | ||
| JP2023546009A5 (enExample) | ||
| JP6878431B2 (ja) | がんに対するメルフルフェン投薬計画 | |
| IL263121A (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| CN111558044A (zh) | 一种包含舒尼替尼的药物组合物及其制剂和应用 | |
| RU2007116850A (ru) | Антагонисты рецептора тромбина | |
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| JP7631319B2 (ja) | 治療方法 | |
| CN111643503A (zh) | 用于治疗非小细胞肺癌的喹啉衍生物 | |
| US20170066795A1 (en) | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv | |
| JP2024509265A5 (enExample) | ||
| JP2024519449A5 (enExample) | ||
| TWI664174B (zh) | 雜環化合物及其用途 | |
| CN111643502A (zh) | 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌 | |
| JP2021107447A5 (enExample) | ||
| JP2010215662A (ja) | １３−デオキシアントラサイクリン誘導体及びその製造方法 | |
| CN115779094A (zh) | 癌症联合治疗的组合物与方法 | |
| EP3956342A1 (en) | Methods and compositions for inhibiting the nlrp3 inflammasome and/or lon protease | |
| TW201932119A (zh) | 膽道癌用抗腫瘤劑和膽道癌的處理方法 | |
| WO2024230772A1 (zh) | 包含抗her2双特异性抗体的联合治疗药物及其用途 |